锂 - 131碘治疗甲状腺毒症的结果。
Results of lithium- 131I treatment of thyrotoxicosis.
作者信息
Brownlie B E, Turner J G, Ovenden B M, Rogers T G
出版信息
J Endocrinol Invest. 1979 Jul-Sep;2(3):303-4. doi: 10.1007/BF03350422.
The role of lithium as an adjunct to 131I therapy of thyrotoxicosis has been assessed. Seventeen lithium- 131I treated patients and 16 control- 131I treated patients have been followed for almost three years. Five lithium- 131I and 3 control- 131I patients have become hypothyroid with the lithium treated patients developing earlier thyroid failure. Ten lithium and 10 control patients remain clinically and biochemically euthyroid. Two lithium- 131I and 2 control- 131I patients remain on low dose antithyroid drugs.
锂作为辅助治疗甲状腺毒症的131I疗法的作用已得到评估。17名接受锂-131I治疗的患者和16名接受对照-131I治疗的患者已被随访近三年。5名接受锂-131I治疗的患者和3名接受对照-131I治疗的患者出现了甲状腺功能减退，接受锂治疗的患者甲状腺功能衰竭出现得更早。10名接受锂治疗的患者和10名对照患者在临床和生化方面仍处于甲状腺功能正常状态。2名接受锂-131I治疗的患者和2名接受对照-131I治疗的患者仍在服用低剂量抗甲状腺药物。
Zotero 插件